Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Apple Turns 50: From Garage Startup to AI Crossroads 
KPMG UK Cuts 440 Audit Jobs Amid Low Attrition and Cooling Professional Services Demand 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SMIC Allegedly Supplies Chipmaking Tools to Iran's Military, U.S. Officials Warn 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
NEW YORK, Dec. 03, 2015 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Valeant Pharmaceuticals International, Inc. (“Valeant Pharmaceuticals”) (NYSE:VRX) between February 23, 2015 and October 20, 2015.
You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the District of New Jersey. To get more information go to:
http://zlk.9nl.com/valeant-pharmaceuticals
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that during the Class Period, defendants made false and misleading statements and/or failed to disclose adverse information about the Company’s business and prospects, including that: (a) the Company was using a network of specialty mail-order pharmacies that it actually controlled to prop up sales of its high-priced drugs and to keep patients and their insurance companies from switching to less costly generic drugs; (b) that Valeant's undisclosed use of specialty pharmacies left it subject to increased regulatory risks; and (c) that without the use of the specialty pharmacies, Valeant’s financial performance and Class Period financial guidance would have been negatively impacted. As a result of these false and misleading statements and/or omissions, Valeant stock traded at artificially inflated prices during the Class Period, reaching over $260 per share.
If you suffered a loss in Valeant Pharmaceuticals you have until December 21, 2015 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com
